Recombinant Human CYP3A7 Protein，His

CYP3A7 is a member of the cytochrome P450 superfamily of enzymes, primarily expressed in the liver and the extrahepatic tissues, including the intestine and adrenal glands. It plays a crucial role in the metabolism of various endogenous and exogenous compounds, including hormones, drugs, and environmental toxins. Unlike its closely related isoforms CYP3A4 and CYP3A5, CYP3A7 exhibits a unique expression pattern, being predominantly active during fetal development and diminishing after birth. This enzymatic activity raises significant interest in pharmacogenomics, as variations in CYP3A7 expression can influence drug metabolism, efficacy, and toxicity in different populations. Studies have shown that polymorphisms in the CYP3A7 gene can lead to altered enzyme activity, impacting the pharmacokinetics of medications metabolized by this pathway. Furthermore, the study of CYP3A7's role in drug interactions and its potential implications in therapeutic drug monitoring has become increasingly relevant, particularly for pregnant women and pediatric patients. The reconstitution of CYP3A7 in vitro allows for detailed characterization of its enzymatic properties and substrate specificity, enabling researchers to better understand its function and relevance in drug metabolism. This knowledge is essential for developing personalized medicine strategies and optimizing drug therapy based on individual genetic makeup. The research on CYP3A7 could unveil new insights into metabolic pathways and contribute to safer, more effective pharmacological care tailored to the needs of diverse patient populations.